Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PCNA | P12004 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | THRA | P10827 | 8/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.75 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.75 |
| ▸ | PPARG | P37231 | 2/20 | 0.75 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.75 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.75 |
| ▸ | HPGD | P15428 | 2/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.75 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.75 |
| ▸ | PGR | P06401 | 1/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825136 | 0.92 | THRB (0.85) | PCNATHRBTHRAPOLBHIF1A | |
| 3,5-Diiodothyropropionic Acid SCHEMBL1501771 | 0.86 | PCNA (1.00) | PCNATHRBTHRAPOLBHIF1A | |
| Tiratricol SCHEMBL25149 | 0.86 | THRB (1.00) | PCNATHRBTHRAPOLBHIF1A | |
| Tiratricol SCHEMBL30161572 | 0.86 | THRB (1.00) | PCNATHRBTHRAPOLBHIF1A | |
| Tiratricol SCHEMBL743426 | 0.86 | THRB (1.00) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL14485260 | 0.85 | PCNA (0.74) | PCNATHRBTHRAPOLBHIF1A | |
| Tiratricol SCHEMBL2671904 | 0.84 | THRB (0.97) | PCNATHRBTHRAPOLBHIF1A | |
| Tiratricol SCHEMBL8660328 | 0.84 | THRB (0.97) | PCNATHRBTHRAPOLBHIF1A | |
| Tiratricol SCHEMBL10701956 | 0.84 | THRB (0.97) | PCNATHRBTHRAPOLBHIF1A | |
| SCHEMBL4238467 | 0.84 | THRB (0.73) | PCNATHRBTHRAPOLBHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 783 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4464721-B1 | HETEROTANDEM BICYCLIC PEPTIDE COMPLEXES | BICYCLETX LTD (GB) | 2025-06-11 | — | — | EP | claimed |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-28 | — | — | US | claimed |
| EP-4271399-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | Vertex Pharmaceuticals Incorporated (US) | 2023-11-08 | — | — | EP | claimed |
| WO-2022147056-A1 | ENHANCED DIFFERENTIATION OF BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-07-07 | — | — | WO | claimed |
| EP-3727460-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EPHA2 | BICYCLETX LTD (GB) | 2022-04-13 | — | — | EP | claimed |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2016-12-22 | — | — | US | claimed |
| US-9328331-B2 | Compositions and methods for promoting beta cell maturity | JOSLIN DIABETES CENTER, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| EP-0831769-B1 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE COMPOUNDS | KAROBIO AB (SE) | 2003-10-15 | — | — | EP | claimed |
| US-20030147815-A1 | Method to treat chronic heart failure and/or elevated cholesterol levels | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA, THE | 2003-08-07 | — | — | US | claimed |
| EP-1328265-A2 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE AGONIST COMPOUNDS FOR TREATING DERMIS CONDITIONS | KARO BIO AB (SE) | 2003-07-23 | — | — | EP | claimed |
| US-20020123521-A1 | Treatment for dermal skin atrophy using thyroid hormone compounds or thyroid hormone-like compounds | KOO, CATHERINE, DR | 2002-09-05 | — | — | US | claimed |
| US-6380255-B1 | TOPICALLY APPLYING TO SKIN THYROID HORMONE COMPOUND TOGETHER WITH A BASE FOR THERAPY OF SKIN ATROPHY | KARO BIO AB (SE) | 2002-04-30 | — | — | US | claimed |
| WO-2002005834-A2 | NOVEL USES FOR THYROID HORMONES OR THYROID HORMONE-LIKE AGONIST COMPOUNDS FOR TREATING DERMIS CONDITIONS | KARO BIO AB (SE) | 2002-01-24 | — | — | WO | claimed |
| US-6221911-B1 | REDUCING SUBCUTANEOUS FAT DEPOSITS IN A SUBJECT; IMPROVING THE SKIN CONDITION OF A SUBJECT | KARO BIO AB (SE) | 2001-04-24 | — | — | US | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0046270-A1 | Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them | INTERx RESEARCH CORPORATION (US) | 1982-02-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | IAPP, ALPG, PNLIP | PCNA 4136/4885THRB 1174/4885THRA 3527/4885 |
| US-20160367645-A1 | LYSOSOMAL ACID LIPASE THERAPY FOR NAFLD AND RELATED DISEASES | LIPC, PNLIP, LIPA | PCNA 4871/4885THRB 2551/4885THRA 2067/4885 |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | PCNA 4349/4885THRB 2436/4885THRA 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.